 Thomas Morrison
Concepts (561)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Chikungunya virus | 40 | 2025 | 80 | 14.490 |
Why?
| | Chikungunya Fever | 35 | 2025 | 79 | 10.960 |
Why?
| | Alphavirus Infections | 29 | 2024 | 44 | 8.340 |
Why?
| | Ross River virus | 19 | 2024 | 23 | 4.630 |
Why?
| | Viral Envelope Proteins | 14 | 2025 | 84 | 4.500 |
Why?
| | Virus Replication | 28 | 2025 | 484 | 3.470 |
Why?
| | Alphavirus | 12 | 2025 | 21 | 2.990 |
Why?
| | Antiviral Agents | 13 | 2025 | 741 | 2.300 |
Why?
| | Interferon Type I | 10 | 2024 | 141 | 2.250 |
Why?
| | Viremia | 5 | 2025 | 138 | 2.050 |
Why?
| | Antibodies, Viral | 16 | 2025 | 624 | 1.960 |
Why?
| | Host-Pathogen Interactions | 9 | 2021 | 364 | 1.950 |
Why?
| | Disease Models, Animal | 28 | 2025 | 4284 | 1.830 |
Why?
| | Antibodies, Neutralizing | 10 | 2025 | 285 | 1.650 |
Why?
| | Animals | 101 | 2025 | 36862 | 1.620 |
Why?
| | Mice | 60 | 2025 | 17774 | 1.530 |
Why?
| | Virulence Factors | 5 | 2018 | 166 | 1.460 |
Why?
| | Receptors, Immunologic | 3 | 2023 | 217 | 1.430 |
Why?
| | Lymph Nodes | 4 | 2024 | 493 | 1.390 |
Why?
| | Viral Nonstructural Proteins | 6 | 2025 | 65 | 1.320 |
Why?
| | Adaptive Immunity | 5 | 2020 | 165 | 1.260 |
Why?
| | Viral Proteins | 12 | 2019 | 343 | 1.190 |
Why?
| | Viral Load | 11 | 2021 | 464 | 1.160 |
Why?
| | Mice, Inbred C57BL | 29 | 2024 | 5753 | 1.160 |
Why?
| | Newcastle disease virus | 13 | 2001 | 17 | 1.150 |
Why?
| | Viruses | 4 | 2022 | 113 | 1.110 |
Why?
| | Encephalitis Virus, Venezuelan Equine | 4 | 2021 | 5 | 1.110 |
Why?
| | Viral Vaccines | 4 | 2022 | 98 | 1.090 |
Why?
| | Phagocytes | 2 | 2025 | 100 | 1.080 |
Why?
| | Monocytes | 4 | 2024 | 563 | 1.040 |
Why?
| | Arthritis | 4 | 2020 | 95 | 1.030 |
Why?
| | Virulence | 11 | 2024 | 265 | 1.010 |
Why?
| | Arginase | 3 | 2015 | 32 | 1.000 |
Why?
| | Encephalomyelitis, Equine | 1 | 2025 | 3 | 0.960 |
Why?
| | Encephalitis Virus, Eastern Equine | 1 | 2025 | 5 | 0.960 |
Why?
| | Clodronic Acid | 1 | 2025 | 17 | 0.920 |
Why?
| | B-Lymphocytes | 4 | 2020 | 846 | 0.910 |
Why?
| | Immune Evasion | 1 | 2025 | 58 | 0.910 |
Why?
| | 3' Untranslated Regions | 2 | 2024 | 145 | 0.860 |
Why?
| | Joints | 4 | 2020 | 105 | 0.840 |
Why?
| | CD8-Positive T-Lymphocytes | 7 | 2025 | 916 | 0.840 |
Why?
| | Interferon Regulatory Factors | 2 | 2022 | 38 | 0.830 |
Why?
| | Immunity, Innate | 7 | 2022 | 827 | 0.830 |
Why?
| | Kupffer Cells | 2 | 2021 | 50 | 0.820 |
Why?
| | RNA Virus Infections | 3 | 2019 | 15 | 0.820 |
Why?
| | RNA, Viral | 14 | 2024 | 654 | 0.810 |
Why?
| | Liposomes | 1 | 2025 | 220 | 0.810 |
Why?
| | Virion | 3 | 2022 | 91 | 0.800 |
Why?
| | Cell Line | 21 | 2024 | 2841 | 0.790 |
Why?
| | Musculoskeletal Diseases | 2 | 2016 | 77 | 0.780 |
Why?
| | Dendritic Cells | 3 | 2024 | 484 | 0.780 |
Why?
| | Adaptor Proteins, Signal Transducing | 5 | 2021 | 429 | 0.750 |
Why?
| | Inflammation | 9 | 2023 | 2836 | 0.730 |
Why?
| | Mice, Knockout | 17 | 2022 | 3009 | 0.710 |
Why?
| | Macrophages | 6 | 2022 | 1544 | 0.710 |
Why?
| | Neutrophils | 2 | 2020 | 1236 | 0.690 |
Why?
| | Viral Fusion Proteins | 8 | 2001 | 17 | 0.690 |
Why?
| | Myeloid Differentiation Factor 88 | 2 | 2020 | 99 | 0.690 |
Why?
| | Capsid Proteins | 3 | 2020 | 94 | 0.670 |
Why?
| | RNA Viruses | 2 | 2019 | 41 | 0.670 |
Why?
| | Myositis | 3 | 2012 | 52 | 0.670 |
Why?
| | Homocystinuria | 1 | 2021 | 71 | 0.660 |
Why?
| | NADPH Oxidase 2 | 1 | 2020 | 39 | 0.660 |
Why?
| | O'nyong-nyong Virus | 1 | 2019 | 4 | 0.650 |
Why?
| | Complement System Proteins | 4 | 2023 | 327 | 0.640 |
Why?
| | Myeloid Cells | 4 | 2024 | 148 | 0.640 |
Why?
| | Quinolones | 1 | 2021 | 137 | 0.640 |
Why?
| | Nitric Oxide Synthase Type II | 1 | 2020 | 173 | 0.630 |
Why?
| | Herpesvirus 4, Human | 4 | 2004 | 167 | 0.630 |
Why?
| | Private Practice | 1 | 2019 | 24 | 0.620 |
Why?
| | Students, Health Occupations | 1 | 2019 | 35 | 0.610 |
Why?
| | Leishmania major | 1 | 2018 | 8 | 0.600 |
Why?
| | Leishmaniasis, Cutaneous | 1 | 2018 | 14 | 0.600 |
Why?
| | Preceptorship | 1 | 2019 | 66 | 0.600 |
Why?
| | Humans | 79 | 2025 | 137294 | 0.590 |
Why?
| | Vero Cells | 11 | 2024 | 68 | 0.590 |
Why?
| | Epitopes, T-Lymphocyte | 4 | 2024 | 187 | 0.570 |
Why?
| | Trans-Activators | 4 | 2004 | 398 | 0.570 |
Why?
| | Osteoarthritis | 1 | 2020 | 185 | 0.560 |
Why?
| | Muscle, Skeletal | 9 | 2020 | 1709 | 0.550 |
Why?
| | Occupational Therapy | 1 | 2019 | 100 | 0.550 |
Why?
| | Pathogen-Associated Molecular Pattern Molecules | 1 | 2017 | 7 | 0.540 |
Why?
| | Endothelial Cells | 5 | 2024 | 779 | 0.520 |
Why?
| | Chronic Disease | 4 | 2019 | 1788 | 0.520 |
Why?
| | Mutation, Missense | 2 | 2019 | 338 | 0.510 |
Why?
| | Gene Deletion | 3 | 2018 | 392 | 0.510 |
Why?
| | Superoxide Dismutase | 1 | 2018 | 346 | 0.510 |
Why?
| | Amino Acid Substitution | 3 | 2014 | 309 | 0.500 |
Why?
| | Disease Outbreaks | 4 | 2023 | 384 | 0.490 |
Why?
| | Zika Virus | 1 | 2017 | 127 | 0.480 |
Why?
| | Immunization | 4 | 2024 | 411 | 0.480 |
Why?
| | Epitopes | 3 | 2025 | 480 | 0.470 |
Why?
| | Zika Virus Infection | 1 | 2017 | 164 | 0.450 |
Why?
| | Complement Activation | 5 | 2018 | 411 | 0.440 |
Why?
| | Tyrosine | 3 | 2013 | 222 | 0.410 |
Why?
| | Membrane Fusion | 3 | 2001 | 39 | 0.410 |
Why?
| | Antigen Presentation | 2 | 2024 | 216 | 0.410 |
Why?
| | Arthralgia | 1 | 2013 | 56 | 0.410 |
Why?
| | Histidine | 1 | 2013 | 64 | 0.400 |
Why?
| | Immunity, Cellular | 1 | 2014 | 268 | 0.400 |
Why?
| | Immunoglobulin G | 5 | 2024 | 886 | 0.380 |
Why?
| | Antibodies, Monoclonal | 5 | 2024 | 1431 | 0.380 |
Why?
| | Sindbis Virus | 4 | 2017 | 10 | 0.370 |
Why?
| | Severe Acute Respiratory Syndrome | 4 | 2018 | 14 | 0.370 |
Why?
| | Signal Transduction | 11 | 2024 | 5078 | 0.370 |
Why?
| | DNA-Binding Proteins | 3 | 2004 | 1501 | 0.370 |
Why?
| | Tenosynovitis | 1 | 2010 | 11 | 0.350 |
Why?
| | Lung | 8 | 2025 | 4067 | 0.350 |
Why?
| | Emergency Responders | 2 | 2021 | 36 | 0.350 |
Why?
| | Up-Regulation | 1 | 2012 | 844 | 0.310 |
Why?
| | Mice, Transgenic | 4 | 2021 | 2164 | 0.310 |
Why?
| | HN Protein | 3 | 1993 | 5 | 0.300 |
Why?
| | Macrophage-1 Antigen | 1 | 2008 | 28 | 0.300 |
Why?
| | Lymphoid Tissue | 2 | 2019 | 75 | 0.300 |
Why?
| | Virus Diseases | 1 | 2011 | 214 | 0.290 |
Why?
| | Spike Glycoprotein, Coronavirus | 4 | 2022 | 108 | 0.290 |
Why?
| | Phenylalanine | 2 | 2022 | 68 | 0.290 |
Why?
| | T-Lymphocytes | 2 | 2019 | 1998 | 0.290 |
Why?
| | Mutation | 7 | 2025 | 3956 | 0.290 |
Why?
| | Arboviruses | 1 | 2008 | 16 | 0.280 |
Why?
| | Cell Membrane | 4 | 2018 | 737 | 0.280 |
Why?
| | Arbovirus Infections | 1 | 2008 | 21 | 0.280 |
Why?
| | Complement C3 | 4 | 2018 | 209 | 0.280 |
Why?
| | Cricetinae | 6 | 2020 | 289 | 0.280 |
Why?
| | Amino Acids | 2 | 2025 | 501 | 0.280 |
Why?
| | Adoptive Transfer | 2 | 2020 | 224 | 0.270 |
Why?
| | Adenoviridae | 2 | 2021 | 193 | 0.270 |
Why?
| | Mutagenesis, Site-Directed | 7 | 2010 | 376 | 0.270 |
Why?
| | Heparitin Sulfate | 2 | 2025 | 50 | 0.260 |
Why?
| | Fibroblasts | 2 | 2024 | 993 | 0.250 |
Why?
| | Orthomyxoviridae Infections | 2 | 2025 | 76 | 0.250 |
Why?
| | West Nile virus | 2 | 2016 | 43 | 0.250 |
Why?
| | Lymphocyte Activation | 3 | 2025 | 1150 | 0.240 |
Why?
| | Phosphoproteins | 3 | 2016 | 338 | 0.240 |
Why?
| | Enzyme Inhibitors | 3 | 2025 | 839 | 0.240 |
Why?
| | RNA Helicases | 1 | 2025 | 30 | 0.240 |
Why?
| | Cysteine Proteases | 1 | 2025 | 7 | 0.240 |
Why?
| | Binding Sites | 3 | 2025 | 1309 | 0.240 |
Why?
| | Cysteine Proteinase Inhibitors | 1 | 2025 | 49 | 0.230 |
Why?
| | Orthobunyavirus | 1 | 2025 | 6 | 0.230 |
Why?
| | Molecular Probes | 1 | 2025 | 36 | 0.230 |
Why?
| | Bunyaviridae Infections | 1 | 2025 | 12 | 0.230 |
Why?
| | Mice, Inbred BALB C | 4 | 2018 | 1269 | 0.230 |
Why?
| | Arthritis, Infectious | 1 | 2006 | 71 | 0.230 |
Why?
| | Lymphocytic choriomeningitis virus | 1 | 2024 | 24 | 0.230 |
Why?
| | Cytokines | 5 | 2020 | 2090 | 0.230 |
Why?
| | Microscopic Polyangiitis | 1 | 2024 | 12 | 0.230 |
Why?
| | Down-Regulation | 2 | 2004 | 658 | 0.230 |
Why?
| | Antibodies, Antineutrophil Cytoplasmic | 1 | 2024 | 36 | 0.220 |
Why?
| | Macaca mulatta | 2 | 2023 | 168 | 0.220 |
Why?
| | Thiazoles | 1 | 2024 | 123 | 0.220 |
Why?
| | Uridine | 1 | 2024 | 30 | 0.220 |
Why?
| | Amides | 1 | 2024 | 93 | 0.220 |
Why?
| | Female | 22 | 2025 | 73052 | 0.220 |
Why?
| | Immunoassay | 2 | 2021 | 113 | 0.220 |
Why?
| | Peroxidase | 1 | 2024 | 176 | 0.220 |
Why?
| | Genome, Viral | 4 | 2019 | 145 | 0.210 |
Why?
| | Genetic Fitness | 1 | 2024 | 57 | 0.210 |
Why?
| | Sequence Deletion | 1 | 2024 | 183 | 0.210 |
Why?
| | Natural Orifice Endoscopic Surgery | 1 | 2023 | 34 | 0.210 |
Why?
| | Membrane Proteins | 2 | 2022 | 1163 | 0.210 |
Why?
| | NADPH Oxidases | 1 | 2024 | 113 | 0.210 |
Why?
| | Australia | 2 | 2022 | 314 | 0.210 |
Why?
| | Receptors, Tumor Necrosis Factor | 1 | 2004 | 164 | 0.210 |
Why?
| | Cell Proliferation | 3 | 2025 | 2479 | 0.210 |
Why?
| | Methionine | 1 | 2024 | 160 | 0.200 |
Why?
| | Ovalbumin | 2 | 2024 | 183 | 0.200 |
Why?
| | Structure-Activity Relationship | 5 | 2025 | 574 | 0.200 |
Why?
| | Antigens, Viral | 2 | 2021 | 181 | 0.200 |
Why?
| | Robotics | 1 | 2023 | 96 | 0.190 |
Why?
| | Killer Cells, Natural | 3 | 2019 | 445 | 0.190 |
Why?
| | Salmonella | 1 | 2022 | 62 | 0.190 |
Why?
| | Robotic Surgical Procedures | 1 | 2023 | 129 | 0.190 |
Why?
| | NF-kappa B | 2 | 2008 | 691 | 0.180 |
Why?
| | Arthritis, Rheumatoid | 1 | 2010 | 1167 | 0.180 |
Why?
| | Transcriptional Activation | 2 | 2022 | 378 | 0.180 |
Why?
| | Base Sequence | 9 | 2010 | 2182 | 0.180 |
Why?
| | Vaccines, Attenuated | 1 | 2022 | 131 | 0.180 |
Why?
| | Benzene Derivatives | 1 | 2021 | 10 | 0.180 |
Why?
| | CD4-Positive T-Lymphocytes | 3 | 2025 | 1095 | 0.180 |
Why?
| | Protein Biosynthesis | 4 | 2019 | 434 | 0.180 |
Why?
| | Gynecology | 1 | 2023 | 176 | 0.180 |
Why?
| | Lung Neoplasms | 2 | 2025 | 2494 | 0.180 |
Why?
| | Mice, Mutant Strains | 1 | 2021 | 298 | 0.180 |
Why?
| | Horses | 1 | 2021 | 111 | 0.180 |
Why?
| | Convalescence | 1 | 2021 | 17 | 0.180 |
Why?
| | Interferon-gamma | 3 | 2010 | 790 | 0.180 |
Why?
| | Protein-Tyrosine Kinases | 2 | 2004 | 434 | 0.170 |
Why?
| | Oligosaccharides | 1 | 2001 | 61 | 0.170 |
Why?
| | Nucleic Acid Conformation | 1 | 2024 | 730 | 0.170 |
Why?
| | Cystathionine beta-Synthase | 1 | 2021 | 71 | 0.170 |
Why?
| | Receptors, Mitogen | 1 | 2020 | 9 | 0.170 |
Why?
| | Oocytes | 2 | 2004 | 180 | 0.170 |
Why?
| | Protein Domains | 1 | 2022 | 290 | 0.170 |
Why?
| | Specimen Handling | 1 | 2022 | 181 | 0.170 |
Why?
| | Xenopus | 1 | 2000 | 87 | 0.170 |
Why?
| | Epstein-Barr Virus Infections | 1 | 2001 | 99 | 0.170 |
Why?
| | Proteome | 1 | 2025 | 472 | 0.170 |
Why?
| | Type C Phospholipases | 1 | 2000 | 74 | 0.170 |
Why?
| | Culicidae | 2 | 2013 | 39 | 0.170 |
Why?
| | Lectins, C-Type | 1 | 2020 | 67 | 0.160 |
Why?
| | Interferon Regulatory Factor-3 | 2 | 2017 | 16 | 0.160 |
Why?
| | Influenza, Human | 2 | 2020 | 625 | 0.160 |
Why?
| | RNA, Messenger | 4 | 2020 | 2839 | 0.160 |
Why?
| | Gene Expression Regulation, Bacterial | 1 | 2022 | 325 | 0.160 |
Why?
| | Tumor Necrosis Factor Receptor Superfamily, Member 9 | 1 | 2019 | 26 | 0.160 |
Why?
| | Glycoproteins | 2 | 2016 | 344 | 0.160 |
Why?
| | Encephalomyelitis, Venezuelan Equine | 1 | 2019 | 1 | 0.160 |
Why?
| | Blood Donors | 1 | 2021 | 103 | 0.160 |
Why?
| | STAT1 Transcription Factor | 2 | 2010 | 73 | 0.160 |
Why?
| | Benzylamines | 1 | 2019 | 41 | 0.160 |
Why?
| | Blotting, Western | 3 | 2015 | 1226 | 0.160 |
Why?
| | Transfection | 7 | 2014 | 947 | 0.160 |
Why?
| | RNA, Double-Stranded | 1 | 2019 | 57 | 0.160 |
Why?
| | Molecular Sequence Data | 7 | 2010 | 2904 | 0.160 |
Why?
| | Primates | 2 | 2017 | 125 | 0.160 |
Why?
| | Laparoscopy | 1 | 2023 | 464 | 0.150 |
Why?
| | Homeodomain Proteins | 3 | 2014 | 506 | 0.150 |
Why?
| | Viral Tropism | 2 | 2019 | 31 | 0.150 |
Why?
| | Parasite Load | 1 | 2018 | 9 | 0.150 |
Why?
| | Diabetes Mellitus, Experimental | 1 | 2020 | 194 | 0.150 |
Why?
| | Leishmania donovani | 1 | 2018 | 12 | 0.150 |
Why?
| | Venules | 1 | 2018 | 14 | 0.150 |
Why?
| | Chemokine CCL21 | 1 | 2018 | 14 | 0.150 |
Why?
| | Single-Cell Analysis | 1 | 2021 | 311 | 0.150 |
Why?
| | Endothelium, Lymphatic | 1 | 2018 | 12 | 0.150 |
Why?
| | Progesterone | 1 | 2000 | 254 | 0.150 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2004 | 1242 | 0.150 |
Why?
| | Genes, Viral | 5 | 2006 | 88 | 0.150 |
Why?
| | src-Family Kinases | 1 | 2019 | 92 | 0.150 |
Why?
| | Problem-Based Learning | 1 | 2019 | 90 | 0.150 |
Why?
| | Breast Neoplasms | 2 | 2025 | 2243 | 0.150 |
Why?
| | Interferon Regulatory Factor-7 | 1 | 2017 | 5 | 0.140 |
Why?
| | Peptides | 1 | 2024 | 982 | 0.140 |
Why?
| | Hindlimb | 2 | 2010 | 128 | 0.140 |
Why?
| | Stromal Cells | 1 | 2018 | 112 | 0.140 |
Why?
| | Heparin-binding EGF-like Growth Factor | 1 | 2017 | 16 | 0.140 |
Why?
| | Antigens, Ly | 1 | 2017 | 44 | 0.140 |
Why?
| | Aedes | 2 | 2019 | 67 | 0.140 |
Why?
| | Canada | 1 | 2019 | 421 | 0.140 |
Why?
| | Receptors, CCR2 | 1 | 2017 | 40 | 0.140 |
Why?
| | Methotrexate | 1 | 2019 | 260 | 0.140 |
Why?
| | Drug Resistance, Viral | 3 | 2025 | 115 | 0.140 |
Why?
| | Diphtheria Toxin | 1 | 2017 | 66 | 0.140 |
Why?
| | Vascular Diseases | 1 | 2020 | 244 | 0.140 |
Why?
| | Gene Expression | 4 | 2015 | 1501 | 0.140 |
Why?
| | Polysaccharides | 1 | 2018 | 84 | 0.140 |
Why?
| | Oxidative Stress | 2 | 2022 | 1315 | 0.140 |
Why?
| | Lysine | 1 | 2019 | 294 | 0.130 |
Why?
| | Protein Processing, Post-Translational | 4 | 2012 | 467 | 0.130 |
Why?
| | Mutant Proteins | 2 | 2014 | 101 | 0.130 |
Why?
| | HeLa Cells | 5 | 2023 | 637 | 0.130 |
Why?
| | Mannose-Binding Lectin | 2 | 2018 | 23 | 0.130 |
Why?
| | Toll-Like Receptors | 1 | 2017 | 185 | 0.130 |
Why?
| | Patient Satisfaction | 1 | 2021 | 657 | 0.130 |
Why?
| | RNA-Binding Proteins | 1 | 2020 | 424 | 0.130 |
Why?
| | Antirheumatic Agents | 1 | 2019 | 292 | 0.130 |
Why?
| | B7-H1 Antigen | 1 | 2018 | 218 | 0.130 |
Why?
| | Male | 13 | 2024 | 67560 | 0.130 |
Why?
| | Sodium-Potassium-Exchanging ATPase | 1 | 2016 | 49 | 0.130 |
Why?
| | Cytoplasm | 2 | 2017 | 272 | 0.120 |
Why?
| | Schistosomiasis mansoni | 1 | 2015 | 23 | 0.120 |
Why?
| | Bacterial Proteins | 1 | 2022 | 895 | 0.120 |
Why?
| | Schistosoma mansoni | 1 | 2015 | 37 | 0.120 |
Why?
| | High-Throughput Nucleotide Sequencing | 1 | 2019 | 537 | 0.120 |
Why?
| | alpha-Synuclein | 1 | 2015 | 34 | 0.120 |
Why?
| | RNA Caps | 1 | 2015 | 35 | 0.120 |
Why?
| | Histocompatibility Antigen H-2D | 1 | 2014 | 21 | 0.120 |
Why?
| | Epidemiological Monitoring | 1 | 2015 | 60 | 0.120 |
Why?
| | Immunoglobulin Fc Fragments | 1 | 2015 | 41 | 0.110 |
Why?
| | Friend murine leukemia virus | 1 | 2015 | 30 | 0.110 |
Why?
| | Communicable Disease Control | 1 | 2015 | 82 | 0.110 |
Why?
| | Cytidine Deaminase | 1 | 2015 | 61 | 0.110 |
Why?
| | Vaccination | 2 | 2021 | 1379 | 0.110 |
Why?
| | Tuberculosis, Pulmonary | 1 | 2015 | 141 | 0.110 |
Why?
| | Mannose-Binding Protein-Associated Serine Proteases | 1 | 2014 | 20 | 0.110 |
Why?
| | Complement Pathway, Mannose-Binding Lectin | 1 | 2014 | 26 | 0.110 |
Why?
| | Animal Structures | 1 | 2014 | 9 | 0.110 |
Why?
| | Pentose Phosphate Pathway | 1 | 2014 | 53 | 0.110 |
Why?
| | Lymphangioleiomyomatosis | 1 | 2014 | 35 | 0.110 |
Why?
| | Gene Expression Regulation, Viral | 2 | 2012 | 93 | 0.110 |
Why?
| | Flow Cytometry | 2 | 2015 | 1184 | 0.110 |
Why?
| | Glycosaminoglycans | 1 | 2013 | 84 | 0.100 |
Why?
| | Caregivers | 1 | 2021 | 876 | 0.100 |
Why?
| | Pandemics | 3 | 2023 | 1623 | 0.100 |
Why?
| | Multiprotein Complexes | 1 | 2014 | 163 | 0.100 |
Why?
| | Protein Kinase Inhibitors | 1 | 2019 | 916 | 0.100 |
Why?
| | ELAV Proteins | 1 | 2012 | 14 | 0.100 |
Why?
| | DNA Mutational Analysis | 1 | 2014 | 400 | 0.100 |
Why?
| | Arthritis, Experimental | 1 | 2014 | 147 | 0.100 |
Why?
| | Interleukin-6 | 2 | 2025 | 778 | 0.100 |
Why?
| | Amino Acid Sequence | 6 | 1994 | 2147 | 0.100 |
Why?
| | Polymerase Chain Reaction | 1 | 2015 | 1061 | 0.100 |
Why?
| | Arthritis, Reactive | 1 | 2012 | 8 | 0.100 |
Why?
| | Mycobacterium tuberculosis | 1 | 2015 | 312 | 0.100 |
Why?
| | Hospitalization | 1 | 2022 | 2214 | 0.100 |
Why?
| | Carrier Proteins | 1 | 2016 | 769 | 0.100 |
Why?
| | Proto-Oncogene Proteins c-akt | 1 | 2014 | 436 | 0.090 |
Why?
| | Mosquito Vectors | 2 | 2024 | 30 | 0.090 |
Why?
| | Synovial Fluid | 2 | 2012 | 69 | 0.090 |
Why?
| | Influenza A Virus, H5N1 Subtype | 1 | 2011 | 8 | 0.090 |
Why?
| | Newcastle Disease | 1 | 1990 | 1 | 0.090 |
Why?
| | Avian Leukosis Virus | 1 | 1990 | 6 | 0.090 |
Why?
| | Reassortant Viruses | 1 | 2010 | 7 | 0.090 |
Why?
| | TOR Serine-Threonine Kinases | 1 | 2014 | 412 | 0.090 |
Why?
| | Protective Agents | 1 | 2011 | 41 | 0.090 |
Why?
| | Time Factors | 3 | 2021 | 6818 | 0.090 |
Why?
| | Seroepidemiologic Studies | 2 | 2021 | 164 | 0.090 |
Why?
| | Emergency Service, Hospital | 1 | 2022 | 2054 | 0.090 |
Why?
| | Cell Survival | 3 | 2021 | 1119 | 0.090 |
Why?
| | Estradiol | 1 | 2014 | 518 | 0.080 |
Why?
| | Transcription, Genetic | 3 | 2004 | 1456 | 0.080 |
Why?
| | Chickens | 1 | 1990 | 191 | 0.080 |
Why?
| | DNA, Viral | 5 | 1993 | 363 | 0.080 |
Why?
| | Receptors, Interferon | 1 | 2010 | 52 | 0.080 |
Why?
| | COS Cells | 2 | 2001 | 188 | 0.080 |
Why?
| | Genetic Vectors | 3 | 2021 | 321 | 0.080 |
Why?
| | CCAAT-Enhancer-Binding Protein-alpha | 1 | 2009 | 15 | 0.080 |
Why?
| | Influenza A Virus, H1N1 Subtype | 1 | 2011 | 152 | 0.080 |
Why?
| | Infant, Newborn | 1 | 2021 | 6054 | 0.080 |
Why?
| | Immunotherapy | 1 | 2014 | 641 | 0.080 |
Why?
| | CCAAT-Enhancer-Binding Protein-beta | 1 | 2009 | 32 | 0.080 |
Why?
| | Receptors, Tumor Necrosis Factor, Type I | 1 | 2009 | 87 | 0.080 |
Why?
| | Calgranulin B | 1 | 2008 | 10 | 0.080 |
Why?
| | Flavivirus Infections | 1 | 2008 | 9 | 0.070 |
Why?
| | Flavivirus | 1 | 2008 | 19 | 0.070 |
Why?
| | Cross-Sectional Studies | 1 | 2019 | 5436 | 0.070 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 3 | 2021 | 851 | 0.070 |
Why?
| | Cricetulus | 3 | 2014 | 109 | 0.070 |
Why?
| | Small Molecule Libraries | 2 | 2019 | 95 | 0.070 |
Why?
| | Histocytochemistry | 1 | 2007 | 79 | 0.070 |
Why?
| | RNA, Small Interfering | 3 | 2020 | 622 | 0.070 |
Why?
| | Promoter Regions, Genetic | 2 | 2009 | 1250 | 0.070 |
Why?
| | Serum | 1 | 2007 | 59 | 0.070 |
Why?
| | Insect Vectors | 1 | 2006 | 39 | 0.060 |
Why?
| | Cells, Cultured | 4 | 2020 | 4197 | 0.060 |
Why?
| | Surveys and Questionnaires | 1 | 2019 | 5769 | 0.060 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2013 | 2195 | 0.060 |
Why?
| | Reactive Oxygen Species | 2 | 2022 | 622 | 0.060 |
Why?
| | RNA Interference | 2 | 2020 | 467 | 0.060 |
Why?
| | Enzyme Activation | 2 | 2014 | 813 | 0.060 |
Why?
| | Mitochondrial Proteins | 1 | 2008 | 256 | 0.060 |
Why?
| | Glycosylation | 2 | 2006 | 163 | 0.060 |
Why?
| | Semliki forest virus | 1 | 2024 | 2 | 0.060 |
Why?
| | Organ Specificity | 1 | 2006 | 304 | 0.060 |
Why?
| | Cysteine Endopeptidases | 1 | 2025 | 72 | 0.060 |
Why?
| | NF-KappaB Inhibitor alpha | 1 | 2004 | 54 | 0.060 |
Why?
| | Chick Embryo | 4 | 1992 | 130 | 0.060 |
Why?
| | Phosphorylation | 4 | 2012 | 1759 | 0.060 |
Why?
| | Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis | 1 | 2024 | 23 | 0.060 |
Why?
| | Genes, Immediate-Early | 1 | 2004 | 21 | 0.060 |
Why?
| | I-kappa B Proteins | 1 | 2004 | 81 | 0.060 |
Why?
| | Sulfones | 1 | 2025 | 110 | 0.060 |
Why?
| | Churg-Strauss Syndrome | 1 | 2024 | 26 | 0.060 |
Why?
| | Active Transport, Cell Nucleus | 1 | 2004 | 123 | 0.060 |
Why?
| | Transcription Factor RelA | 1 | 2004 | 88 | 0.050 |
Why?
| | Intercellular Adhesion Molecule-1 | 1 | 2004 | 139 | 0.050 |
Why?
| | Plasmids | 3 | 1991 | 362 | 0.050 |
Why?
| | Granulomatosis with Polyangiitis | 1 | 2024 | 44 | 0.050 |
Why?
| | Immediate-Early Proteins | 1 | 2004 | 49 | 0.050 |
Why?
| | Glomerulonephritis | 1 | 2024 | 47 | 0.050 |
Why?
| | CHO Cells | 2 | 2014 | 161 | 0.050 |
Why?
| | Anaerobiosis | 1 | 2024 | 64 | 0.050 |
Why?
| | HEK293 Cells | 2 | 2019 | 731 | 0.050 |
Why?
| | Brain | 1 | 2015 | 2675 | 0.050 |
Why?
| | Cell Line, Transformed | 1 | 2004 | 145 | 0.050 |
Why?
| | Centrifugation, Density Gradient | 2 | 2001 | 41 | 0.050 |
Why?
| | Peptidyl-Dipeptidase A | 1 | 2023 | 52 | 0.050 |
Why?
| | Culture Media, Conditioned | 1 | 2023 | 110 | 0.050 |
Why?
| | Cloning, Molecular | 3 | 2008 | 536 | 0.050 |
Why?
| | Respiration | 1 | 2024 | 198 | 0.050 |
Why?
| | Recombinant Fusion Proteins | 2 | 2009 | 664 | 0.050 |
Why?
| | Protein Tyrosine Phosphatases | 1 | 2004 | 172 | 0.050 |
Why?
| | Bone and Bones | 1 | 2006 | 316 | 0.050 |
Why?
| | Coculture Techniques | 1 | 2023 | 239 | 0.050 |
Why?
| | Neoplasm Metastasis | 1 | 2025 | 658 | 0.050 |
Why?
| | Body Weight | 1 | 2007 | 985 | 0.050 |
Why?
| | Keratinocytes | 1 | 2004 | 248 | 0.050 |
Why?
| | Minimally Invasive Surgical Procedures | 1 | 2023 | 181 | 0.050 |
Why?
| | Epithelium | 1 | 2023 | 312 | 0.050 |
Why?
| | Immunity, Humoral | 1 | 2023 | 117 | 0.050 |
Why?
| | Salmonella typhimurium | 1 | 2024 | 183 | 0.050 |
Why?
| | DNA-Directed RNA Polymerases | 1 | 2022 | 57 | 0.050 |
Why?
| | Basal Ganglia Diseases | 1 | 2001 | 8 | 0.050 |
Why?
| | Survival Analysis | 2 | 2015 | 1321 | 0.050 |
Why?
| | Central Nervous System Vascular Malformations | 1 | 2001 | 25 | 0.050 |
Why?
| | Cross Protection | 1 | 2021 | 5 | 0.050 |
Why?
| | Sulfonamides | 1 | 2025 | 512 | 0.050 |
Why?
| | World Health Organization | 1 | 2022 | 123 | 0.050 |
Why?
| | Cell Nucleus | 1 | 2004 | 617 | 0.040 |
Why?
| | Cross Reactions | 1 | 2021 | 133 | 0.040 |
Why?
| | Mitochondria | 1 | 2008 | 947 | 0.040 |
Why?
| | Oxidoreductases Acting on CH-CH Group Donors | 1 | 2021 | 26 | 0.040 |
Why?
| | Microsomes, Liver | 1 | 2021 | 86 | 0.040 |
Why?
| | Half-Life | 1 | 2021 | 165 | 0.040 |
Why?
| | Microspheres | 1 | 2021 | 137 | 0.040 |
Why?
| | Child | 1 | 2021 | 21999 | 0.040 |
Why?
| | Immunity | 1 | 2001 | 144 | 0.040 |
Why?
| | Molecular Docking Simulation | 1 | 2021 | 112 | 0.040 |
Why?
| | Colorado | 2 | 2021 | 4527 | 0.040 |
Why?
| | Tyrphostins | 1 | 2000 | 18 | 0.040 |
Why?
| | Interleukin-1 | 1 | 2004 | 964 | 0.040 |
Why?
| | Phosphotyrosine | 1 | 2000 | 39 | 0.040 |
Why?
| | Giant Cells | 2 | 1998 | 24 | 0.040 |
Why?
| | Genetic Engineering | 1 | 2021 | 92 | 0.040 |
Why?
| | Phosphoserine | 1 | 2000 | 34 | 0.040 |
Why?
| | Metformin | 1 | 2004 | 330 | 0.040 |
Why?
| | Immunoglobulin M | 1 | 2022 | 288 | 0.040 |
Why?
| | Cell Adhesion Molecules, Neuronal | 1 | 2020 | 41 | 0.040 |
Why?
| | Severity of Illness Index | 1 | 2008 | 2836 | 0.040 |
Why?
| | Fluorescent Antibody Technique | 1 | 2001 | 388 | 0.040 |
Why?
| | Kinetics | 2 | 2013 | 1674 | 0.040 |
Why?
| | GTP-Binding Proteins | 1 | 2000 | 161 | 0.040 |
Why?
| | NIH 3T3 Cells | 1 | 2019 | 144 | 0.040 |
Why?
| | Cell Line, Tumor | 2 | 2020 | 3414 | 0.040 |
Why?
| | Cell Adhesion Molecules | 1 | 2020 | 181 | 0.040 |
Why?
| | Tumor Suppressor Protein p53 | 1 | 2023 | 530 | 0.040 |
Why?
| | Early Detection of Cancer | 1 | 2023 | 419 | 0.040 |
Why?
| | Cadherins | 1 | 2020 | 205 | 0.040 |
Why?
| | Protein Transport | 2 | 2012 | 444 | 0.040 |
Why?
| | Poly I-C | 1 | 2018 | 63 | 0.040 |
Why?
| | Interferon-beta | 2 | 2009 | 92 | 0.040 |
Why?
| | Trypsin | 1 | 1998 | 77 | 0.040 |
Why?
| | Autocrine Communication | 1 | 2018 | 41 | 0.040 |
Why?
| | Receptor, Interferon alpha-beta | 1 | 2018 | 35 | 0.040 |
Why?
| | Molecular Structure | 1 | 2019 | 498 | 0.040 |
Why?
| | Adaptor Proteins, Vesicular Transport | 1 | 2018 | 45 | 0.040 |
Why?
| | High-Throughput Screening Assays | 1 | 2019 | 160 | 0.030 |
Why?
| | Paracrine Communication | 1 | 2018 | 65 | 0.030 |
Why?
| | Spleen | 1 | 2019 | 514 | 0.030 |
Why?
| | Chemokines | 1 | 2018 | 228 | 0.030 |
Why?
| | Antigens, CD | 1 | 2020 | 522 | 0.030 |
Why?
| | Ischemia | 1 | 2020 | 407 | 0.030 |
Why?
| | Eukaryotic Initiation Factors | 1 | 2016 | 10 | 0.030 |
Why?
| | Phosphatidylinositol 3-Kinases | 1 | 2019 | 365 | 0.030 |
Why?
| | Capsid | 1 | 2017 | 93 | 0.030 |
Why?
| | Biological Transport | 3 | 1992 | 417 | 0.030 |
Why?
| | Ribosomal Protein S6 Kinases, 70-kDa | 1 | 2016 | 35 | 0.030 |
Why?
| | Virus Assembly | 1 | 2017 | 77 | 0.030 |
Why?
| | Hyperglycemia | 1 | 2020 | 347 | 0.030 |
Why?
| | Ouabain | 1 | 2016 | 16 | 0.030 |
Why?
| | Length of Stay | 1 | 2022 | 1218 | 0.030 |
Why?
| | Digoxin | 1 | 2016 | 30 | 0.030 |
Why?
| | Sensitivity and Specificity | 1 | 2021 | 1946 | 0.030 |
Why?
| | Gene Expression Regulation | 2 | 2020 | 2608 | 0.030 |
Why?
| | Atherosclerosis | 1 | 2020 | 415 | 0.030 |
Why?
| | Transcription Factors | 1 | 2004 | 1720 | 0.030 |
Why?
| | Monensin | 2 | 1985 | 4 | 0.030 |
Why?
| | Carbonyl Cyanide m-Chlorophenyl Hydrazone | 2 | 1985 | 4 | 0.030 |
Why?
| | Granuloma | 1 | 2015 | 91 | 0.030 |
Why?
| | Gene Expression Profiling | 2 | 2014 | 1774 | 0.030 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2019 | 2052 | 0.030 |
Why?
| | Viral Plaque Assay | 2 | 1992 | 31 | 0.030 |
Why?
| | Apoptosis | 1 | 2004 | 2554 | 0.030 |
Why?
| | International Cooperation | 1 | 2015 | 199 | 0.030 |
Why?
| | Glucose Transporter Type 2 | 1 | 2014 | 15 | 0.030 |
Why?
| | NADP | 1 | 2014 | 50 | 0.030 |
Why?
| | Vesicular stomatitis Indiana virus | 1 | 1974 | 13 | 0.030 |
Why?
| | Reticulocytes | 1 | 1974 | 18 | 0.030 |
Why?
| | Glucose Transporter Type 1 | 1 | 2014 | 50 | 0.030 |
Why?
| | Virus Attachment | 1 | 2013 | 16 | 0.030 |
Why?
| | Clinical Trials as Topic | 1 | 2019 | 1045 | 0.030 |
Why?
| | RNA Stability | 1 | 2015 | 117 | 0.030 |
Why?
| | Transduction, Genetic | 1 | 2014 | 126 | 0.030 |
Why?
| | Calcium | 1 | 2000 | 1198 | 0.030 |
Why?
| | Drug Implants | 1 | 2014 | 82 | 0.030 |
Why?
| | Virus Internalization | 1 | 2013 | 49 | 0.030 |
Why?
| | Glucosephosphate Dehydrogenase | 1 | 2014 | 60 | 0.030 |
Why?
| | Precipitin Tests | 1 | 1993 | 100 | 0.030 |
Why?
| | Static Electricity | 1 | 2013 | 120 | 0.030 |
Why?
| | Mechanistic Target of Rapamycin Complex 1 | 1 | 2014 | 125 | 0.030 |
Why?
| | Hydrogen Bonding | 1 | 2013 | 169 | 0.030 |
Why?
| | Mice, SCID | 1 | 2014 | 367 | 0.030 |
Why?
| | Cell Fusion | 1 | 1993 | 52 | 0.030 |
Why?
| | Reproducibility of Results | 1 | 2021 | 3283 | 0.030 |
Why?
| | Conserved Sequence | 1 | 1993 | 240 | 0.030 |
Why?
| | Oligodeoxyribonucleotides | 1 | 1993 | 143 | 0.020 |
Why?
| | Protein Multimerization | 1 | 2013 | 193 | 0.020 |
Why?
| | Cell Cycle Proteins | 1 | 2016 | 613 | 0.020 |
Why?
| | Endosomes | 1 | 2013 | 136 | 0.020 |
Why?
| | Alternative Splicing | 1 | 2014 | 229 | 0.020 |
Why?
| | Protein Binding | 2 | 2009 | 2225 | 0.020 |
Why?
| | Global Health | 1 | 2015 | 386 | 0.020 |
Why?
| | Biomarkers | 1 | 2023 | 4164 | 0.020 |
Why?
| | Tumor Suppressor Proteins | 1 | 2014 | 327 | 0.020 |
Why?
| | Proteolysis | 1 | 2012 | 178 | 0.020 |
Why?
| | Caspases | 1 | 2012 | 247 | 0.020 |
Why?
| | Viral Structural Proteins | 1 | 1991 | 12 | 0.020 |
Why?
| | Poultry | 1 | 1990 | 10 | 0.020 |
Why?
| | Prospective Studies | 1 | 2023 | 7595 | 0.020 |
Why?
| | Complement C5a | 1 | 2011 | 71 | 0.020 |
Why?
| | Tritium | 2 | 1985 | 76 | 0.020 |
Why?
| | Orthomyxoviridae | 1 | 1991 | 43 | 0.020 |
Why?
| | Electrophoresis, Polyacrylamide Gel | 2 | 1985 | 345 | 0.020 |
Why?
| | Vaccines, Synthetic | 1 | 1990 | 126 | 0.020 |
Why?
| | DNA | 2 | 1988 | 1459 | 0.020 |
Why?
| | Polyribosomes | 2 | 1984 | 24 | 0.020 |
Why?
| | Chloramphenicol O-Acetyltransferase | 1 | 2009 | 38 | 0.020 |
Why?
| | In Situ Hybridization | 1 | 2010 | 316 | 0.020 |
Why?
| | Insulin | 1 | 2000 | 2406 | 0.020 |
Why?
| | Antibody Formation | 1 | 1990 | 298 | 0.020 |
Why?
| | Magnetic Resonance Imaging | 1 | 2001 | 3568 | 0.020 |
Why?
| | Receptors, CCR | 1 | 2008 | 8 | 0.020 |
Why?
| | Electrophoretic Mobility Shift Assay | 1 | 2009 | 85 | 0.020 |
Why?
| | Virus Cultivation | 1 | 2008 | 29 | 0.020 |
Why?
| | Chromatin Immunoprecipitation | 1 | 2009 | 138 | 0.020 |
Why?
| | Glucose | 1 | 2014 | 1028 | 0.020 |
Why?
| | Immunoblotting | 1 | 2009 | 307 | 0.020 |
Why?
| | Middle Aged | 2 | 2021 | 33310 | 0.020 |
Why?
| | Metabolomics | 1 | 2014 | 679 | 0.020 |
Why?
| | Genotype | 1 | 2013 | 1923 | 0.020 |
Why?
| | Models, Molecular | 1 | 2013 | 1594 | 0.020 |
Why?
| | Oligonucleotides | 1 | 2009 | 148 | 0.020 |
Why?
| | Seasons | 1 | 2011 | 545 | 0.020 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2010 | 976 | 0.020 |
Why?
| | Genes | 1 | 1988 | 230 | 0.020 |
Why?
| | Mitochondrial Membranes | 1 | 2008 | 38 | 0.020 |
Why?
| | Statistics, Nonparametric | 1 | 2008 | 431 | 0.020 |
Why?
| | Protein Conformation | 2 | 1992 | 940 | 0.020 |
Why?
| | Neurons | 1 | 2015 | 1588 | 0.020 |
Why?
| | DNA, Recombinant | 1 | 1986 | 47 | 0.020 |
Why?
| | Risk Factors | 1 | 2021 | 10368 | 0.020 |
Why?
| | Nucleic Acid Hybridization | 1 | 1986 | 190 | 0.020 |
Why?
| | Mercaptoethanol | 1 | 1985 | 11 | 0.020 |
Why?
| | Retrospective Studies | 1 | 2023 | 15639 | 0.010 |
Why?
| | Open Reading Frames | 1 | 2006 | 119 | 0.010 |
Why?
| | Fucose | 1 | 1985 | 3 | 0.010 |
Why?
| | Rats | 1 | 2014 | 5639 | 0.010 |
Why?
| | Disulfides | 1 | 1985 | 107 | 0.010 |
Why?
| | Immune System | 1 | 2006 | 177 | 0.010 |
Why?
| | Poly A | 1 | 1984 | 51 | 0.010 |
Why?
| | Protein Tyrosine Phosphatase, Non-Receptor Type 1 | 1 | 2004 | 47 | 0.010 |
Why?
| | Xenopus laevis | 1 | 2004 | 106 | 0.010 |
Why?
| | Proto-Oncogene Proteins c-jun | 1 | 2004 | 55 | 0.010 |
Why?
| | Receptor, Insulin | 1 | 2004 | 105 | 0.010 |
Why?
| | Response Elements | 1 | 2004 | 91 | 0.010 |
Why?
| | Computational Biology | 1 | 2008 | 646 | 0.010 |
Why?
| | RNA | 1 | 2010 | 924 | 0.010 |
Why?
| | Models, Genetic | 1 | 2006 | 607 | 0.010 |
Why?
| | Protein Structure, Tertiary | 1 | 2004 | 867 | 0.010 |
Why?
| | Basal Ganglia | 1 | 2001 | 56 | 0.010 |
Why?
| | Adult | 2 | 2021 | 37724 | 0.010 |
Why?
| | Recombinant Proteins | 1 | 2004 | 1354 | 0.010 |
Why?
| | Hypoglycemic Agents | 1 | 2004 | 1283 | 0.010 |
Why?
| | Carcinoma, Krebs 2 | 1 | 1974 | 1 | 0.010 |
Why?
| | Electrophoresis, Paper | 1 | 1974 | 1 | 0.010 |
Why?
| | Chromatography, Paper | 1 | 1974 | 3 | 0.010 |
Why?
| | Sulfur Radioisotopes | 1 | 1974 | 15 | 0.010 |
Why?
| | Chromatography | 1 | 1974 | 24 | 0.010 |
Why?
| | Hydroxyapatites | 1 | 1974 | 13 | 0.010 |
Why?
| | Carbon Radioisotopes | 1 | 1974 | 34 | 0.010 |
Why?
| | Tissue Extracts | 1 | 1974 | 19 | 0.010 |
Why?
| | Peptide Biosynthesis | 1 | 1974 | 13 | 0.010 |
Why?
| | Autoradiography | 1 | 1974 | 78 | 0.010 |
Why?
| | Cell-Free System | 1 | 1974 | 53 | 0.010 |
Why?
| | Triticum | 1 | 1974 | 17 | 0.010 |
Why?
| | Peptide Chain Initiation, Translational | 1 | 1974 | 44 | 0.010 |
Why?
| | Genetic Complementation Test | 1 | 1992 | 66 | 0.010 |
Why?
| | Viral Matrix Proteins | 1 | 1992 | 30 | 0.010 |
Why?
| | Rabbits | 1 | 1974 | 793 | 0.010 |
Why?
| | Sequence Alignment | 1 | 1992 | 345 | 0.010 |
Why?
|
|
Morrison's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|